\
&
Contact us
\
&
Contact us
Published on | 1 year ago
Programmes EITthe HORIZON-EIT-2024-WomenInnovatorsPrize call is now open for applications on the EU funding and tender portal. Deadline is 25 September 2024.
The European Prize for Women Innovators celebrates the women entrepreneurs behind Europe’s game-changing innovations, so that they may inspire other women and girls realise their full potential as the EU’s future scientists, innovators, and tech leaders.
This prize supports a culture within research and innovation organisations and companies allowing women to become the innovators and entrepreneurs of tomorrow.
The prize is awarded every year to women from across the EU and countries associated to Horizon Europe, who have transformed their ideas into disruptive innovations to benefit people and the planet.
Expected Impact:
The prize will boost public awareness of the potential, importance and contribution of women to the EU innovation ecosystem and create strong role models, inspiring more women to become innovators themselves.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
